Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 4/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321215 | 0.82 | KCNH2 (0.44) | CYP2A6HTR2ASMN1; SMN2TAAR1LOXL2 | |
| SCHEMBL6956035 | 0.78 | TAAR1 (0.44) | TAAR1 | |
| SCHEMBL8325538 | 0.76 | SCN4A (0.40) | SCN4AHTR2ASMN1; SMN2DPP4 | |
| SCHEMBL205556 | 0.75 | ALDH1A1 (0.52) | CYP2A6HTR2ASMN1; SMN2TAAR1LOXL2 | |
| SCHEMBL392681 | 0.75 | AOC3 (0.43) | — | |
| SCHEMBL8067078 | 0.74 | ANPEP (0.50) | SCN4ACYP2A6HTR2ASMN1; SMN2TAAR1 | |
| SCHEMBL855071 | 0.74 | ANPEP (0.50) | SCN4ACYP2A6HTR2ASMN1; SMN2TAAR1 | |
| SCHEMBL5924988 | 0.74 | ANPEP (0.50) | SCN4ACYP2A6HTR2ASMN1; SMN2TAAR1 | |
| SCHEMBL7597898 | 0.74 | KCNH2 (0.42) | GRIK1HTR2AKCNH2 | |
| SCHEMBL7844501 | 0.73 | KCNH2 (0.52) | HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | GRIK1 1186/4885SCN4A 1042/4885CYP2A6 4204/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | GRIK1 872/4885SCN4A 3619/4885CYP2A6 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.